MITO Stealth BioTherapeutics Corp. ADRs

We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. We believe our lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases.  This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$1.28  +0.01 (0.39%)
As of 04/14/2021 15:40:34 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Cayman Islands
Country of incorporation:  
IPO date:  02/15/2019
Outstanding shares:  55,434,562
Average volume:  256,148
Market cap:   $70,401,894
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    85789A105
ISIN:        US85789A1051
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   27.61
PS ratio:   0.00
Return on equity:   553.96%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy